logo
How the bubonic plague has survived for centuries

How the bubonic plague has survived for centuries

Yahoo29-05-2025
The catastrophic loss of life at the hands of a single bacterium during the 14th century remains one of human history's most devastating events. Yersinia pestis–the bacterium that causes bubonic plague–managed to survive for centuries by adjusting its severity and the length of time it takes to kill its hosts. Despite that virulence, some forms of plague did ultimately die out. Now, scientists have documented the way that one single gene in Yersinia pestis made it so adaptable. The findings are described in a study published May 29 in the journal Science.
[ Related: Bubonic plague discovered in ancient Egyptian mummy DNA. ]
According to the Cleveland Clinic, there are three types of plague. Which type that you have depends on where in your body Yersinia pestis ends up. Bubonic plague infects the lymph nodes, septicemic plague is in the blood, and pneumonic plague affects the lungs.
Yersinia pestis itself is a bacterium with some deep historical roots and has caused three major pandemics in recorded human history.
The Plague of Justinian in the mid-500s is the first recorded plague pandemic in human history. It is named for Justinian I, the Byzantine emperor at that time, and it devastated the Mediterranean region. Mortality estimates vary between 25 million and 100 million deaths. It killed roughly 40 percent of Constantinople's (now Istanbul) population, which was the most important center of cultural and political life in the world. at the time.
It eventually led to the second plague pandemic–the Black Death in the 14th century. The Black Death is still the deadliest pandemic in recorded human history, killing 30 to 50 percent of the population in Europe, Western Asia, and Africa. The disease re-emerged in several waves over more than 500 years and persisted in that form until 1840.
The third plague pandemic began in China in 1855 and continues today. Antibiotics have significantly helped treat the disease, but its impacts are still felt in parts of Madagascar and the Democratic Republic of Congo, where cases are regularly reported.
Strains of the original Justinian plague went extinct after 300 years of wreaking havoc on European and Middle Eastern populations. The strains that caused the Black Death emerged from infected rodents before it broke into two major lineages. One of these two lineages is the ancestor of the present-day strains, while the other strain re-emerged over centuries in Europe and went extinct by the early 19th century.
'This is one of the first research studies to directly examine changes in an ancient pathogen, one we still see today, in an attempt to understand what drives the virulence, persistence and/or eventual extinction of pandemics,' Hendrik Poinar, a study co-author and molecular evolutionary geneticist and biological anthropologist at McMaster University in Canada, said in a statement.
In the new study, the team used hundreds of samples from ancient and modern plague victims. They screened the samples for a gene known as pla. This gene helps Yersinia pestis move through the body's immune system undetected by the lymph nodes before it spreads to the rest of the body.
The genetic analysis revealed that its copy number–the total number of pla genes found in the bacterium–actually decreased in the later plague outbreaks. This decreased mortality by about 20 percent, while increasing the length of infection. The hosts typically lived longer before they died. These studies were performed in mice models of bubonic plague, according to the team.
When the pla gene was in its original, high copy number, the disease was much more virulent. It killed all of its hosts and did so much quicker.
Additionally, the team also pinpointed a similarity between the trajectories of both modern and ancient strains. These strains independently evolved similar reductions in the pla gene during the later stages of the first and second plague pandemics and in three samples from the third pandemic that were uncovered in present day Vietnam.
In both the Justinian plague from the 500s and the Black Death, the evolutionary change occurred approximately 100 years after the first outbreaks. The team believes that when the gene copy number dropped and the infected rats lived longer, the rodents could spread infection farther. This spread helped ensure the pathogen's reproductive success.
'The reduction of pla may reflect the changing size and density of rodent and human populations,' explained Poinar. 'It's important to remember that plague was an epidemic of rats, which were the drivers of epidemics and pandemics. Humans were accidental victims.'
Due to their high numbers and proximity to humans, the black rats in cities likely acted as 'amplification hosts.' Since these black rats are highly susceptible to Yersinia pestis themselves, the pathogen needed the rat populations to stay high enough to supply new hosts for Yersinia pestis to persist and allow the natural pandemic cycle to continue.
[ Related: DNA from plague victims' teeth may unravel the origin of Black Death. ]
However, the strains of plague that did not have the pla gene eventually went extinct. This likely reflects another shift that occurred in the host-pathogen relationship within their environment.
When the team searched for signs of pla gene depletion in samples of the third plague pandemic preserved in a large collection at the Institut Pasteur in Paris, they found three contemporary strains with the pla depletion. The diminished virulence that the pathogen evolved in response to more of its hosts dying potentially caused these earlier plague pandemics to fizzle out.
'Thanks to our international collaborators who monitor local epidemics of plague worldwide, we were able to find the unique bacterial samples used for this project, akin to finding of three rare needles in a haystack,' Javier Pizarro-Cerdá, a study co-author and microbiologist who specializes in plague at the Institut Pasteur, said in a statement.
Despite this evolution, most of the strains circulating in some countries in Africa, South America, and Asia are more virulent.
'Today, the plague is a rare disease, but one that remains a public health concern and serves as a model for gaining a broad understanding of how pandemics emerge and become extinct,' said Javier Pizarro-Cerdá. 'This example illustrates the balance of virulence a pathogen can adopt in order to spread effectively from one host to another.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Administration Halts NIH From Issuing Any New Research Grants
Trump Administration Halts NIH From Issuing Any New Research Grants

Forbes

time2 hours ago

  • Forbes

Trump Administration Halts NIH From Issuing Any New Research Grants

The White House Office of Management and Budget (OMB), led by Director Russell Vought (C) seen here ... More with U.S. President Donald Trump (L), is reportedly blocking the National Institutes of Health from issuing any new funding to grantees and contractors. (Photo by ANDREW CABALLERO-REYNOLDS/AFP via Getty Images) Things just got even tougher for science and scientists around the country and the countless patients and other people that their research could eventually benefit. For the past several months, many researchers in the U.S. have already had to deal with kind of a 'cancel culture' with their grants from the National Institutes of Health being abruptly held, cut or terminated if certain words, phrases or concepts appeared in them that didn't correspond with what the Trump Administration wanted. And now the Trump Administration is putting an immediate 'pause' on the NIH's ability to issue any new research grants, contracts or training awards to anyone outside the NIH. The OMB Blocks The NIH From Providing New Funding Yep, Angus Chen, Megan Molteni, and Anil Oza just reported for STAT how this directive came out of the White House Office of Management and Budget and was delivered as a four-sentence email to the directors of NIH institutes and centers on Tuesday afternoon. The email referred to a 'footnote' from the OMB regarding funding for the NIH and indicated that the U.S. Department of Health and Human Services 'has interpreted this footnote' to mean that new funding from the NIH would be prohibited for now but the NIH is 'working to make this limitation short-term and temporary.' That footnote could end up being quite a kick to the rears of grantees, awardees and contractors in universities, medical centers and other research organizations around the country. It looks like any researcher expecting to receive funds from the NIH through either new awards or renewals of current awards may have to wait for it, wait for it, wait until who knows what needs to happen. Neither the OMB nor the NIH have clarified what will happen and what needs to happen to make funding available again. (I am reaching out to contacts at HHS and NIH for further comment.) This situation basically further handcuffs the NIH's ability to use money that Congress already allocated to the NIH to use this fiscal year. It's kind of like of your parents giving you an allowance and then someone else saying, 'Oh you can't use that.' NIH Employees Prohibited From Spending Money On Purchases Or Travel The OMB footnote will do some further kicking to those working within the NIH as well. That is those still working within the NIH. Since U.S. President Donald Trump took office, there have been multiple waves of different Rs at the NIH. And these Rs haven't exactly been rest and relaxation. They've been rounds of resignations, retirements and RIFs—meaning reductions in force. The remaining NIH employees will reportedly not be able to spend any more money on purchases or travel until the end of the current government fiscal year, which will be September 30. Unspent NIH Funds Would Return To The U.S. Treasury After September 30 Speaking of the government fiscal year. Being only two months away from its end raises an even bigger concern. If this situation isn't 'short-term' and 'temporary' enough, it could soon become quite permanent. Once September 30 passes, money unspent by the NIH would automatically go back to the U.S. Treasury. So, in two months, researchers might have to sing 'bye-bye-bye' to the funding they thought they would receive. That certanly wouldn't be in sync with any of their staffing and scientific plans. This so-called 'temporary' situation could be a way of cutting NIH funding in a manner that bypasses Congress. This office of Senator Patty Murray (D-Washington) has estimated that the funds currently hanging in the balance may total around $15 billion. NIH Funding Halt May Cause Even More Job Loss I've written previously in Forbes about how the cutting and canceling of research grants will cause job loss. Unless we've entered some other world in the multi-verse, that still hold. Many scientists depend on NIH funding to pay their own salaries and fringe benefits as well those of their research staffs. When it's not clear when and if expected funding will arrive, there's only so long researchers can hold on, in the words of Wilson Phillips, before they have to lay off people or even lose their own positions. And once a researcher or research staff member is lost, it can be tough to replace them. It's not as if you are simply looking for something to post something dumb on social media or be featured in the reality TV show 'Cheaters.' The U.S. doesn't have an unlimited supply of those with appropriate scientific talent, skills and drive. It can take a lot of time to find someone with the right stuff to fill a position. You can't simply tell the coaches or managers of the Los Angeles Dodgers, Philadelphia Eagles or Oklahoma City Thunder, 'Yeah, we know that you have been sort of successful. But we won't allow you to pay your players, so you are going to have to cut them. Oh, but don't worry, some day when you do have money, we aren't saying when and how, you can always find new players.' NIH Funding Halt Will Have Widespread Ramifcations On Health And The Economy If you don't do any scientific research and think this NIH funding halt won't affect you, think again. It's not as if the NIH funded researchers out there are spending their days posting random rants on social media. They are working hard, often day and night, on ways to prevent and treat different disease such as cardiovascular disease, diabetes, obesity, cancer and a whole range of different infectious diseases, including those that may cause the 'p' word some day. Who knows how many lives will end being affected by these interruptions, disruptions and stoppages of such work? And no matter how healthy you think you are right now, no matter how much kombucha, eyes of newt or whatever you are consuming right now, you will run into health problems some day. You, your family members and your friends will. Trying to keep as many Americans as healthy as possible shouldn't be a political thing. More Americans being healthy longer would mean more Americans to work and produce for society longer. That should be a win-win situation. Or a win-win-win situation. More legit biomedical and health research as opposed to more let's-just-say-it-happens-woo-woo should help the economy as well. More science-backed stuff would mean more stable and sustainable health products and interventions that can form the basis of more sustainable businesses. Yet, this 'pause' in NIH funding is yet another blow to science, scientific research and all of the above. It should give everyone pause to think about what's really important for this country and whether things are headed in the right direction in U.S. After all, this latest 'temporary' situation with NIH may not end up being temporary at all.

This Hamilton-built AI could change how lung cancer is diagnosed in Canada
This Hamilton-built AI could change how lung cancer is diagnosed in Canada

Hamilton Spectator

time4 hours ago

  • Hamilton Spectator

This Hamilton-built AI could change how lung cancer is diagnosed in Canada

Lung cancer is not only the most commonly diagnosed cancer in Canada, it has an abysmally low survival rate of 25 per cent over a five-year period. Often, by the time it is correctly spotted, it is in an advanced stage and has spread to other parts of the body. A chief culprit for these bleak statistics is modern technology, which has surprisingly failed to advance lung cancer's timely detection. Now, however, NodeAI, a medical technology startup out of Hamilton, aims to upend this dismal trend with its novel, AI-powered diagnostic procedure that promises to save more lives with a startling 100 per cent increase in accuracy rates. Its new test will also pare sky-high diagnostic and treatment costs. 'It helps to decide if patients should go to the operating room or if they should go to the cancer centre and have chemotherapy,' explains NodeAI co-founder Dr. Waël Hanna, one of Canada's leading thoracic surgeons who practices at St. Joe's hospital in Hamilton, and is the brains behind NodeAI's solution. Hanna is also a pioneer in robotic surgery in the country and the head of the thoracic surgery division at McMaster University. Lung cancer diagnosis hinges on a crucial litmus test — determining if lymph nodes in the chest region are cancerous or not. 'Before you decide on treatment of lung cancer, whether it's surgery or chemotherapy or anything else, you have to evaluate the lymph nodes,' says Hanna. If they are found to be malignant, this often means that the cancer has spread to other parts of the body; in other words, escalated from stages 1, 2 or 3 to Stage 4. Dr. Waël Hanna, thoracic surgeon at St. Joe's Hospital and the brains behind his company's AI-powered solution that doubles the accuracy in detecting lung cancer A long-standing method of doing so is the endobronchial ultrasound-guided transbronchial needle aspiration — a mouthful, but commonly referred to as EBUS-TBNA. It involves sending a bronchoscope — a thin tube with a light and camera at the end — down the throat and into the chest in order to relay ultrasound images of the lymph nodes to an external screen. If the lymph nodes look compromised, a thin needle is then sent down the same path to extract a tissue sample, called a biopsy, in order to test for cancer. The problem is, the EBUS-TBNA procedure is both ancient and inaccurate. 'Ultrasound is very operator dependent, meaning that you and me can look at the same ultrasound image and only 20 per cent of the time will we agree on what it shows,' says Hanna. Which means, the decision to biopsy a lymph node — not an inexpensive process — is hit or miss. Errors result in unnecessary procedures, treatments and costs. Several years ago, Hanna was sitting contemplating this problem as well as the thousands of images of lymph nodes and associated lungs that he had instinctively squirrelled away over a decade of research and surgery. 'He had the foresight to keep these images as part of a research program because he thought, 'What else can be done with this?'' says Mackensey Bacon, co-founder and CEO of NodeAI, who is also a manager with the Research Institute of St. Joe's in Hamilton. Doing so is unusual. 'Say you have an ultrasound image for fetal monitoring when you have a baby, and they take a picture of that — it's stored as part of your medical record. But for lymph nodes, it's purely used as a guidance tool,' explains Bacon. 'It's not stored as part of the medical record.' That fateful day, when Hanna picked up his iPhone and unlocked it by looking at it, as most iPhone users tend to do, a light bulb went off. 'What if you could use this image-recognition technology to marry these records toward some kind of diagnostic tool?' he wondered. Hanna got in touch with Anthony Gatti, an expert in AI-driven medical imaging and currently a post-doctoral scholar in radiology at Stanford University and a co-founder of NodeAI, to engineer a solution. This ultimately involved training an algorithm on Hanna's treasure trove of images, and NodeAI's solution was born. Using deep neural network models and a data set of 2,569 images of lymph nodes, NodeAI's technology can now supercharge a EBUS-TBNA procedure. In under six seconds, it can compare a patient's lymph nodes to its own data set of cancerous lymph nodes and lungs in real time and deliver a reading with 85 per cent accuracy compared to 40 per cent previously. This vast improvement will save a considerable amount of time and money on costly — and often unnecessary — biopsies and flawed treatments plans. The innovation was good enough to win the $100,000 Ernsting Entrepreneurship prize in March — a highly competitive award given to one of six finalists in who are picked for their innovative technologies that detect or treat cancers. The award was part of Falcons' Fortunes pitch competition, currently in its 12th year, orchestrated by FACIT, a commercialization venture firm that helps accelerate oncology innovation in Ontario and has attracted more than $1.6 billion in investment to Ontario. 'I think we're all very passionate about improving care and cancer, which hits home to me,' says NodeAI CEO Bacon, whose father succumbed to chronic myeloid leukemia in Hamilton when she was four years old. 'It has been a motivator for me throughout my entire career,' she adds. The company is currently trialing its technology at the top cancer hospitals in Ontario, Alberta, Manitoba and Quebec, and is on its way to securing FDA and Health Canada approvals. 'Take all the cancers that you know of. Add them up together in terms of how many people they kill,' explains Hanna. 'All combined, they will kill less people than lung cancer every year.' NodeAI's AI-powered ultrasounds hopes to change that soon. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

There's a tree in California that's older than the Egyptian pyramids
There's a tree in California that's older than the Egyptian pyramids

Yahoo

time10 hours ago

  • Yahoo

There's a tree in California that's older than the Egyptian pyramids

BIG PINE, Calif. (FOX 5/KUSI) — Hidden high in the White Mountains of eastern California, a gnarled, weathered tree quietly holds a staggering secret — it's nearly 5,000 years old. Known as the Methuselah Tree, this Great Basin bristlecone pine (Pinus longaeva) is one of the oldest known living trees on Earth, having sprouted around 2830 BCE — over a century before the Egyptian pyramids rose from the sands. Nestled within the Inyo National Forest's Ancient Bristlecone Pine Forest, the Methuselah Tree has long fascinated scientists, historians, and nature lovers alike. Its twisted trunk and timeworn branches are shaped by millennia of harsh winds, snow and sun, standing as a living witness to human history. Methuselah was once considered the oldest living non-clonal tree in the world — meaning it has survived as the same individual organism for nearly 5 millennia. Although other slightly older bristlecones have since been discovered, Methuselah remains one of the most iconic ancient trees on the planet. California State Parks rolls out new reservation upgrades to help campers find perfect site A tree older than civilization A tree's age is usually determined by counting its growth rings. Each year, a tree adds a new ring to its trunk, so the number of rings shows how old it is. Scientists don't have to cut the tree down to count the rings. Instead, they use a special tool to take a thin core sample from the trunk. To put the Methuselah Tree's age in perspective: It began growing centuries years before the Great Pyramid of Giza was built, and it was already over 3,000 years old when Julius Caesar ruled Rome. Despite its fame, the exact location of the Methuselah Tree is kept secret by the U.S. Forest Service to protect it from vandalism and foot traffic. Visitors to the Methuselah Grove can hike the area's scenic trails, which feature other bristlecone pines estimated to be thousands of years old. Why bristlecones live so long The Great Basin bristlecone pine thrives in extreme conditions where few other trees can survive — high altitudes, rocky soil, and low moisture. This tough environment actually contributes to the species' longevity. As explained by officials with U.S. Department of Agriculture, slow growth, dense wood, and natural resilience make bristlecones incredibly durable over time. Scientists continue to study the Methuselah Tree and its ancient relatives to gain insight into climate patterns, forest ecosystems, and tree aging. Hike to the world's largest wooden trestle bridge — it's in Southern California Trekking the Methuselah Trail For those seeking a walk through living history, the Methuselah Trail offers a rare, humbling encounter with the endurance of nature. Visitors can explore the area by hiking a 4.5-mile loop, considered moderate by popular hiking app AllTrails, that winds through the grove where many of these old trees grow. The trail and forest are open seasonally, typically from late spring through fall, depending on weather conditions. Be prepared for the high elevation — the trail sits at over 9,000 feet above sea level. It's recommended to bring plenty of water, wear sunscreen, and be aware of potential altitude effects. According to the U.S. Forest Service, the Methuselah Tree can technically be seen along this trail, but there is not a sign that points it out. Do you think you can spot it? As the world changes around us, the Methuselah Tree stands quietly on its windswept ridge, reminding us of nature's resilience — and the importance of preserving it for generations to come. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store